Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
Discover Oncology
Published in: Discover Oncology 1/2023

Open Access 01-12-2023 | Gastric Cancer | Review

Emerging roles of noncoding RNAs in human cancers

Authors: Shijie Wu, Yiwen Wu, Sijun Deng, Xiaoyong Lei, Xiaoyan Yang

Published in: Discover Oncology | Issue 1/2023

Login to get access

Abstract

Studies have found that RNA encoding proteins only account for a small part of the total number, most RNA is non-coding RNA, and non-coding RNA may affect the occurrence and development of human cancers by affecting gene expression, therefore play an important role in human pathology. At present, ncRNAs studied include miRNA, circRNA, lncRNA, piRNA, and snoRNA, etc. After decades of research, the basic role of these ncRNAs in many cancers has been clear. As far as we know, the role of miRNAs in cancer is one of the hottest research directions, however, it is also found that the imbalance of ncRNAs will affect the occurrence of gastric cancer, breast cancer, lung cancer, meanwhile, it may also affect the prognosis of these cancers. Therefore, the study of ncRNAs in cancers may help to find new cancer diagnostic and treatment methods. Here, we reviewed the biosynthesis and characteristics of miRNA, cricRNA, and lncRNA etc., their roles in human cancers, as well as the mechanism through which these ncRNAs affect human cancers.
Literature
1.
2.
3.
4.
Ling H, Fabbri M, Calin GA. MicroRNAs and other non-coding RNAs as targets for anticancer drug development. Nat Rev Drug Discovery. 2013;12(11):847–65.CrossRefPubMed
5.
6.
7.
8.
Lee Y, et al. The nuclear RNase III Drosha initiates microRNA processing. Nature. 2003;425(6956):415–9.CrossRefPubMed
9.
Krol J, Loedige I, Filipowicz W. The widespread regulation of microRNA biogenesis, function and decay. Nat Rev Genet. 2010;11(9):597–610.CrossRefPubMed
10.
11.
Yu B, et al. The FHA domain proteins DAWDLE in Arabidopsis and SNIP1 in humans act in small RNA biogenesis. Proc Natl Acad Sci U S A. 2008;105(29):10073–8.PubMedCentralCrossRefPubMed
12.
Pu M, et al. Regulatory network of miRNA on its target: coordination between transcriptional and post-transcriptional regulation of gene expression. Cell Mol Life Sci. 2019;76(3):441–51.CrossRefPubMed
13.
Bhaskaran M, Mohan M. MicroRNAs: history, biogenesis, and their evolving role in animal development and disease. Vet Pathol. 2014;51(4):759–74.CrossRefPubMed
14.
15.
Rybak-Wolf A, et al. Circular RNAs in the mammalian brain are highly abundant, conserved, and dynamically expressed. Mol Cell. 2015;58(5):870–85.CrossRefPubMed
16.
17.
Bachmayr-Heyda A, et al. Correlation of circular RNA abundance with proliferation–exemplified with colorectal and ovarian cancer, idiopathic lung fibrosis, and normal human tissues. Sci Rep. 2015;5:8057.PubMedCentralCrossRefPubMed
18.
Moldovan LI, et al. High-throughput RNA sequencing from paired lesional- and non-lesional skin reveals major alterations in the psoriasis circRNAome. BMC Med Genomics. 2019;12(1):174.PubMedCentralCrossRefPubMed
19.
Memczak S, et al. Circular RNAs are a large class of animal RNAs with regulatory potency. Nature. 2013;495(7441):333–8.CrossRefPubMed
20.
21.
22.
23.
van Zonneveld AJ, et al. Circular RNAs in kidney disease and cancer. Nat Rev Nephrol. 2021;17(12):814–26.CrossRefPubMed
24.
Kristensen LS, et al. The biogenesis, biology and characterization of circular RNAs. Nat Rev Genet. 2019;20(11):675–91.CrossRefPubMed
25.
26.
27.
Hansen TB, et al. Natural RNA circles function as efficient microRNA sponges. Nature. 2013;495(7441):384–8.CrossRefPubMed
28.
29.
30.
31.
32.
33.
34.
Mercer TR, Dinger ME, Mattick JS. Long non-coding RNAs: insights into functions. Nat Rev Genet. 2009;10(3):155–9.CrossRefPubMed
35.
Roberts TC, Morris KV, Wood MJA. The role of long non-coding RNAs in neurodevelopment, brain function and neurological disease. Philosophical Trans Royal Soc B: Biol Sci. 2014;369(1652):20130507.CrossRef
36.
Mukherjee N, et al. Integrative classification of human coding and noncoding genes through RNA metabolism profiles. Nat Struct Mol Biol. 2017;24(1):86–96.CrossRefPubMed
37.
38.
Beaulieu YB, et al. Polyadenylation-dependent control of long noncoding RNA expression by the poly(A)-binding protein nuclear 1. PLoS Genet. 2012;8(11):e1003078.PubMedCentralCrossRefPubMed
39.
Brown JA, et al. Formation of triple-helical structures by the 3’-end sequences of MALAT1 and MENβ noncoding RNAs. Proc Natl Acad Sci U S A. 2012;109(47):19202–7.PubMedCentralCrossRefPubMed
40.
Schmidt K, et al. Targeting the oncogenic long non-coding RNA SLNCR1 by blocking its sequence-specific binding to the androgen receptor. Cell Rep. 2020;30(2):541–554e5.PubMedCentralCrossRefPubMed
41.
42.
43.
44.
Czech B, et al. piRNA-Guided Genome Defense: from Biogenesis to silencing. Annu Rev Genet. 2018;52:131–57.CrossRefPubMed
45.
Ozata DM, et al. PIWI-interacting RNAs: small RNAs with big functions. Nat Rev Genet. 2019;20(2):89–108.CrossRefPubMed
46.
47.
48.
49.
Xiao L, et al. Disorders and roles of tsRNA, snoRNA, snRNA and piRNA in cancer. J Med Genet. 2022;59(7):623–31.CrossRefPubMed
50.
Egloff S, O’Reilly D, Murphy S. Expression of human snRNA genes from beginning to end. Biochem Soc Trans. 2008;36(Pt 4):590–4.CrossRefPubMed
51.
van der Werf J, Chin CV, Fleming NI. SnoRNA in Cancer progression metastasis and immunotherapy response. Biology (Basel). 2021;10(8):809.PubMed
52.
53.
54.
55.
Vogelstein B, et al. Cancer genome landscapes Science. 2013;339(6127):1546–58.PubMed
56.
Kontomanolis EN, et al. Role of oncogenes and tumor-suppressor genes in carcinogenesis: a review. Anticancer Res. 2020;40(11):6009–15.CrossRefPubMed
57.
Kopnin BP. Targets of oncogenes and tumor suppressors: key for understanding basic mechanisms of carcinogenesis. Biochem (Mosc). 2000;65(1):2–27.
58.
59.
60.
Wang LH, et al. Loss of tumor suppressor gene function in Human Cancer: an overview. Cell Physiol Biochem. 2018;51(6):2647–93.CrossRefPubMed
61.
Lin Y, Xu J, Lan H. Tumor-associated macrophages in tumor metastasis: biological roles and clinical therapeutic applications. J Hematol Oncol. 2019;12(1):76.PubMedCentralCrossRefPubMed
62.
Mun EJ, et al. Tumor-treating Fields: a fourth modality in Cancer Treatment. Clin Cancer Res. 2018;24(2):266–75.CrossRefPubMed
63.
64.
Li Z, Feiyue Z, Gaofeng L. Traditional chinese medicine and lung cancer–from theory to practice. Biomed Pharmacother. 2021;137:111381.CrossRefPubMed
65.
66.
Carleton M, Cleary MA, Linsley PS. MicroRNAs and cell cycle regulation. Cell Cycle. 2007;6(17):2127–32.CrossRefPubMed
67.
Lau NC, et al. An abundant class of tiny RNAs with probable regulatory roles in Caenorhabditis elegans. Science. 2001;294(5543):858–62.CrossRefPubMed
68.
69.
Nakamura T, Canaani E, Croce CM. Oncogenic All1 fusion proteins target Drosha-mediated microRNA processing. Proc Natl Acad Sci U S A. 2007;104(26):10980–5.PubMedCentralCrossRefPubMed
70.
Yanaihara N, et al. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell. 2006;9(3):189–98.CrossRefPubMed
71.
Iorio MV, et al. MicroRNA gene expression deregulation in human breast cancer. Cancer Res. 2005;65(16):7065–70.CrossRefPubMed
72.
73.
74.
Ling H, et al. Non-coding RNAs: the cancer genome dark matter that matters! Clin Chem Lab Med. 2017;55(5):705–14.CrossRefPubMed
75.
Qattan A, et al. Robust expression of tumor suppressor miRNA’s let-7 and miR-195 detected in plasma of saudi female breast cancer patients. BMC Cancer. 2017;17(1):799.PubMedCentralCrossRefPubMed
76.
Cha YH, et al. MiRNA-34 intrinsically links p53 tumor suppressor and wnt signaling. Cell Cycle. 2012;11(7):1273–81.CrossRefPubMed
77.
78.
Malayaperumal S, et al. A review of AEG-1 Oncogene regulating MicroRNA expression in Colon cancer progression. Endocr Metab Immune Disord Drug Targets. 2021;21(1):27–34.CrossRefPubMed
79.
Costinean S, et al. Pre-B cell proliferation and lymphoblastic leukemia/high-grade lymphoma in Eµ-miR155 transgenic mice. Proc Natl Acad Sci. 2006;103(18):7024–9.PubMedCentralCrossRefPubMed
80.
Medina PP, Nolde M, Slack FJ. OncomiR addiction in an in vivo model of microRNA-21-induced pre-B-cell lymphoma. Nature. 2010;467(7311):86–90.CrossRefPubMed
81.
82.
83.
84.
Voorhoeve PM, et al. A genetic screen implicates miRNA-372 and miRNA-373 as oncogenes in testicular germ cell tumors. Adv Exp Med Biol. 2007;604:17–46.CrossRefPubMed
85.
86.
Chen S, et al. The function of RAS Mutation in Cancer and advances in its Drug Research. Curr Pharm Des. 2019;25(10):1105–14.CrossRefPubMed
87.
Ma L, Teruya-Feldstein J, Weinberg RA. Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature. 2007;449(7163):682–8.CrossRefPubMed
88.
Tian XP, et al. Acidic microenvironment up-regulates exosomal miR-21 and miR-10b in early-stage hepatocellular carcinoma to promote cancer cell proliferation and metastasis. Theranostics. 2019;9(7):1965–79.PubMedCentralCrossRefPubMed
89.
Nicoloso MS, et al. MicroRNAs–the micro steering wheel of tumour metastases. Nat Rev Cancer. 2009;9(4):293–302.CrossRefPubMed
90.
91.
Mokhtari M, Rouhanizadeh N, Hajialiasgar S. Investigation of microRNA-10b values for the discrimination of metastasis due to melanoma. J Res Med Sci. 2021;26:108.PubMedCentralCrossRefPubMed
92.
93.
94.
Murphy ST, et al. Discovery of novel, potent, and selective inhibitors of 3-phosphoinositide-dependent kinase (PDK1). J Med Chem. 2011;54(24):8490–500.CrossRefPubMed
95.
Zeng Y, et al. A circular RNA binds to and activates AKT phosphorylation and nuclear localization reducing apoptosis and enhancing Cardiac Repair. Theranostics. 2017;7(16):3842–55.PubMedCentralCrossRefPubMed
96.
de Gómez M, Ramírez de A, Molina. Microtargeting cancer metabolism: opening new therapeutic windows based on lipid metabolism. J Lipid Res. 2016;57(2):193–206.CrossRef
97.
98.
99.
Zhang M, et al. A novel protein encoded by the circular form of the SHPRH gene suppresses glioma tumorigenesis. Oncogene. 2018;37(13):1805–14.CrossRefPubMed
100.
Chen RX, et al. Circular RNA circRNA_0000285 promotes cervical cancer development by regulating FUS. Eur Rev Med Pharmacol Sci. 2019;23(20):8771–8.PubMed
101.
102.
Zong ZH, et al. CircWHSC1 promotes ovarian cancer progression by regulating MUC1 and hTERT through sponging miR-145 and miR-1182. J Exp Clin Cancer Res. 2019;38(1):437.PubMedCentralCrossRefPubMed
103.
104.
105.
106.
Huang X, et al. Circular RNA AKT3 upregulates PIK3R1 to enhance cisplatin resistance in gastric cancer via miR-198 suppression. Mol Cancer. 2019;18(1):71.PubMedCentralCrossRefPubMed
107.
108.
109.
110.
111.
112.
Rui X, et al. LncRNA GAS6-AS2 promotes bladder cancer proliferation and metastasis via GAS6-AS2/miR-298/CDK9 axis. J Cell Mol Med. 2019;23(2):865–76.CrossRefPubMed
113.
Hu Q, Tai S, Wang J. Oncogenicity of lncRNA FOXD2-AS1 and its molecular mechanisms in human cancers. Pathol Res Pract. 2019;215(5):843–8.CrossRefPubMed
114.
115.
116.
117.
Arora R, Brun CM, Azzalin CM. TERRA: long noncoding RNA at eukaryotic telomeres. Prog Mol Subcell Biol. 2011;51:65–94.CrossRefPubMed
118.
Zhang X, et al. Maternally expressed gene 3, an imprinted noncoding RNA gene, is associated with meningioma pathogenesis and progression. Cancer Res. 2010;70(6):2350–8.PubMedCentralCrossRefPubMed
119.
Chak WP, et al. Downregulation of long non-coding RNA MEG3 in nasopharyngeal carcinoma. Mol Carcinog. 2017;56(3):1041–54.CrossRefPubMed
120.
Li J, et al. Epigenetic repression of long non-coding RNA MEG3 mediated by DNMT1 represses the p53 pathway in gliomas. Int J Oncol. 2016;48(2):723–33.CrossRefPubMed
121.
Ying L, et al. Downregulated MEG3 activates autophagy and increases cell proliferation in bladder cancer. Mol Biosyst. 2013;9(3):407–11.CrossRefPubMed
122.
Sedaghati M, Kebebew E. Long noncoding RNAs in thyroid cancer. Curr Opin Endocrinol Diabetes Obes. 2019;26(5):275–81.CrossRefPubMed
123.
Li H, et al. PCAT-1 contributes to cisplatin resistance in gastric cancer through epigenetically silencing PTEN via recruiting EZH2. J Cell Biochem. 2020;121(2):1353–61.CrossRefPubMed
124.
Wang H, et al. HOTAIR enhanced paclitaxel and doxorubicin resistance in gastric cancer cells partly through inhibiting miR-217 expression. J Cell Biochem. 2018;119(9):7226–34.CrossRefPubMed
125.
Xu W, et al. Silencing of lncRNA ZFAS1 inhibits malignancies by blocking Wnt/β-catenin signaling in gastric cancer cells. Biosci Biotechnol Biochem. 2018;82(3):456–65.CrossRefPubMed
126.
127.
Xian HP, et al. Circulating long non-coding RNAs HULC and ZNFX1-AS1 are potential biomarkers in patients with gastric cancer. Oncol Lett. 2018;16(4):4689–98.PubMedCentralPubMed
128.
Cui Y, et al. LncRNA FAM230B promotes gastric Cancer Growth and Metastasis by regulating the miR-27a-5p/TOP2A Axis. Dig Dis Sci. 2021;66(8):2637–50.CrossRefPubMed
129.
Hashim A, et al. RNA sequencing identifies specific PIWI-interacting small non-coding RNA expression patterns in breast cancer. Oncotarget. 2014;5(20):9901–10.PubMedCentralCrossRefPubMed
130.
131.
132.
133.
Williams GT, Farzaneh F. Are snoRNAs and snoRNA host genes new players in cancer? Nat Rev Cancer. 2012;12(2):84–8.CrossRefPubMed
134.
Aksoy-Aksel A, Zampa F, Schratt G. MicroRNAs and synaptic plasticity—a mutual relationship. Philosophical Trans Royal Soc B: Biol Sci. 2014;369(1652):20130515.CrossRef
135.
Roberts TC, Morris KV, Wood MJ. The role of long non-coding RNAs in neurodevelopment, brain function and neurological disease. Philos Trans R Soc Lond B Biol Sci. 2014;369:1652.CrossRef
136.
Sone M, et al. The mRNA-like noncoding RNA Gomafu constitutes a novel nuclear domain in a subset of neurons. J Cell Sci. 2007;120(Pt 15):2498–506.CrossRefPubMed
137.
138.
Zhang Y, et al. MiRNA-27a decreases ultraviolet B irradiation-induced cell damage. J Cell Biochem. 2020;121(2):1032–8.CrossRefPubMed
139.
Li Y, et al. Isoliquiritin ameliorates depression by suppressing NLRP3-mediated pyroptosis via miRNA-27a/SYK/NF-κB axis. J Neuroinflammation. 2021;18(1):1.PubMedCentralCrossRefPubMed
140.
141.
Yu X, et al. miR-96-5p: a potential diagnostic marker for gestational diabetes mellitus. Med (Baltim). 2021;100(21):e25808.CrossRef
142.
Deleavey GF, Damha MJ. Designing chemically modified oligonucleotides for targeted gene silencing. Chem Biol. 2012;19(8):937–54.CrossRefPubMed
143.
Watts JK, Corey DR. Silencing disease genes in the laboratory and the clinic. J Pathol. 2012;226(2):365–79.CrossRefPubMed
144.
Lu D, Thum T. RNA-based diagnostic and therapeutic strategies for cardiovascular disease. Nat Rev Cardiol. 2019;16(11):661–74.CrossRefPubMed
145.
Sun Y, et al. Enhancing the therapeutic delivery of oligonucleotides by chemical modification and nanoparticle encapsulation. Molecules. 2017;22(10):1724.PubMedCentralCrossRefPubMed
146.
Di Martino MT, et al. Synthetic miR-34a mimics as a novel therapeutic agent for multiple myeloma: in vitro and in vivo evidence. Clin Cancer Res. 2012;18(22):6260–70.PubMedCentralCrossRefPubMed
147.
Poller W, et al. Non-coding RNAs in cardiovascular diseases: diagnostic and therapeutic perspectives. Eur Heart J. 2018;39(29):2704–16.CrossRefPubMed
148.
Parashar D, et al. Lipid-based nanocarriers for delivery of small interfering RNA for therapeutic use. Eur J Pharm Sci. 2020;142:105159.CrossRefPubMed
149.
Metadata
Title
Emerging roles of noncoding RNAs in human cancers
Authors
Shijie Wu
Yiwen Wu
Sijun Deng
Xiaoyong Lei
Xiaoyan Yang
Publication date
01-12-2023
Publisher
Springer US
Published in
Discover Oncology / Issue 1/2023
Print ISSN: 1868-8497
Electronic ISSN: 2730-6011
DOI
https://doi.org/10.1007/s12672-023-00728-w

Other articles of this Issue 1/2023

Discover Oncology 1/2023 Go to the issue

Research

Radiotherapy combined with anti-CEACAM1 immunotherapy to induce survival advantage in glioma

Research

Circ_0000182 promotes cholesterol synthesis and proliferation of stomach adenocarcinoma cells by targeting miR-579-3p/SQLE axis

Brief Communication

Antitumor activity of 5-fluorouracil polymeric nanogel synthesized by gamma radiation on a rat model of colon carcinoma: a proposed mechanism

Research

Infection with COVID-19 promotes the progression of pancreatic cancer through the PI3K-AKT signaling pathway

Research

Geriatric nutritional risk index as a prognostic marker of first-line immune checkpoint inhibitor combination therapy in patients with renal cell carcinoma: a retrospective multi-center study

Brief Communication

Preliminary results from the EMoLung clinical study showing early lung cancer detection by the LC score
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits